Those who call for FDA to adopt comparative effectiveness as a regulatory third leg are laser-beam focused on cost effectiveness. What's important is to understand the unintended consequences of such rhetoric on pharmaceutical innovation.
For a brief lesson on the environment in which innovation operates, see here.
Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.
